Physician profile
Anthony Schore
NPI 1861538431
$16,959.87
in general payments reported to CMS, 2019-2025
47 companies · $3,428 in 2025
The $3,428 reported for 2025 was more than what 88% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,824 · 2020: $778 · 2021: $2,064 · 2022: $2,698 · 2023: $2,775 · 2024: $3,393 · 2025: $3,428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,556 · Education: $39.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,556.49 |
| Education | $39.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,306.18 | 2019-2025 | Linzess, Rinvoq, Skyrizi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,774.01 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Gilead Sciences, INC. | $1,369.09 | 2019-2025 | |
| Janssen Biotech, INC. | $1,235.90 | 2019-2025 | Stelara, Simponi, Simponi Aria |
| Celgene Corporation | $936.38 | 2021-2024 | Zeposia |
| Pfizer INC. | $930.50 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $599.10 | 2019-2024 | Trulance, Xifaxan |
| Ironwood Pharmaceuticals, INC | $472.13 | 2019-2024 | Linzess |
| Lilly USA, LLC | $440.53 | 2024-2025 | Omvoh, Zepbound |
| Intercept Pharmaceuticals, INC. | $424.51 | 2019-2025 | Ocaliva |
| Ardelyx, INC. | $424.13 | 2022-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $389.17 | 2024-2025 | Rezdiffra, Resmetirom |
| Phathom Pharmaceuticals, INC. | $347.63 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $347.59 | 2019-2024 | Dificid |
| Qol Medical, LLC | $305.64 | 2019-2025 | Sucraid |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $214.44 | 2019-2022 | |
| Redhill Biopharma INC. | $196.32 | 2020-2023 | Talicia, Aemcolo, Movantik |
| Exact Sciences Corporation | $192.59 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Ipsen Biopharmaceuticals, INC | $188.77 | 2024-2025 | Iqirvo |
| Allergan, INC. | $179.90 | 2019-2020 | |
| Medtronic, INC. | $170.95 | 2021-2025 | Barrx |
| Novo Nordisk INC | $151.76 | 2024-2025 | Wegovy |
| Celltrion USA INC. | $130.99 | 2024-2025 | Vegzelma, Zymfentra |
| Evoke Pharma, INC. | $128.45 | 2021-2023 | Gimoti |
| Organon LLC | $119.99 | 2021-2025 | Hadlima, Renflexis |
| Aimmune Therapeutics, INC. | $116.79 | 2024-2025 | Zenpep |
| Genzyme Corporation | $107.69 | 2024 | |
| Covidien LP | $96.00 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $91.27 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $72.49 | 2022-2024 | Dupixent |
| Amgen INC. | $55.50 | 2023 | Avsola, Amjevita |
| Fresenius Kabi USA, LLC | $49.79 | 2023 | Idacio |
| Laborie Medical Technologies Corp. | $38.64 | 2025 | Alphaone |
| Lucid Diagnostics INC. | $38.18 | 2023-2024 | |
| Fujifilm Healthcare Americas Corporation | $37.72 | 2022 | |
| Shionogi INC | $37.23 | 2019-2020 | |
| Shire North American Group INC | $36.14 | 2019 | |
| Nestle Healthcare Nutrition INC. | $35.87 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $23.50 | 2024 | Dojolvi |
| Pharmacosmos Therapeutics INC. | $22.90 | 2021 | |
| Tanabe Pharma America, INC. | $21.48 | 2019 | |
| Teleflex LLC | $19.11 | 2023 | Urolift |
| Intra-Sana Laboratories | $18.64 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Ferring Pharmaceuticals INC. | $18.29 | 2019 | |
| Braintree Laboratories, INC. | $17.62 | 2025 | Suflave, Sutab |
| Alfasigma USA, INC. | $15.74 | 2020 | |
| Amag Pharmaceuticals, INC. | $12.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Schore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.